Acrannolife Genomics

What Acrannolife Genomics does

Acrannolife Genomics Private Limited is an Indian precision diagnostics company founded in 2014 and headquartered in Chennai, Tamil Nadu. The company has developed a proprietary liquid biopsy platform called Trunome that analyzes cell-free DNA (cfDNA) and donor-derived cell-free DNA (ddcfDNA) from blood samples to enable non-invasive monitoring of chronic diseases, with its primary commercial application being post-transplant organ health monitoring across kidney, liver, heart, lung, and pancreas transplants. The Trunome platform is described as the first entirely made-in-India liquid biopsy technology in Asia and is protected by a US patent along with over 10 additional patented technologies.

The company's second product line targets infectious diseases using isothermal amplification technology. COVIQWIK is an RT-LAMP COVID-19 testing kit developed in collaboration with ICMR-NIV that produces results in 30-60 minutes with claimed 100% sensitivity and specificity, and TBFYND is a CDSCO-approved LAMP-based tuberculosis detection kit with 98.73% accuracy and 100% specificity designed for point-of-care use without elaborate laboratory infrastructure. Upcoming Trunome modules for oncology and women's health are listed on the company website as 'Coming Soon'.

Commercially, Acrannolife distributes diagnostic services through hospital and transplant center partnerships, direct patient inquiry channels, and government health programs, with an indigenous manufacturing facility being established at TANSIDCO Industrial Estate with financial support from India's Technology Development Board. The company is founder-controlled by brothers Avinash Ramani (CSO) and Agragesh Ramani (CEO), is privately held with no disclosed institutional venture capital, has 1-10 employees, and has been funded primarily through government grants and recognition programs including ET-POI, IIGP (Stanford/DST/FICCI), and Aatma Nirbhar Bharat designation.

Name

Acrannolife Genomics

Legal name

Acrannolife Genomics Private Limited

Website

https://acrannolife.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Acrannolife Genomics is an India-based precision diagnostics company operating a proprietary Trunome liquid biopsy platform for non-invasive post-transplant organ rejection monitoring (kidney, liver, heart, lungs, pancreas), alongside ICMR-validated COVIQWIK COVID-19 and CDSCO-approved TBFYND tuberculosis point-of-care kits.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Liquid Biopsy

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Liquid biopsy diagnostics
• Transplant rejection monitoring
• Infectious disease testing kits
• Molecular diagnostic platform
• Point-of-care diagnostics

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services (Trunome): Revenue generated from providing liquid biopsy tests for post-transplant organ health monitoring. Tests are offered through hospitals, transplant centers, and directly to patients via inquiry. The company provides specialized care solutions for post-transplant recovery and long-term health monitoring of kidney, liver, heart, lungs, and pancreas transplants.
2. COVID-19 Testing Kits (COVIQWIK): Sale of RT-LAMP based COVID-19 testing kits to institutions, hospitals, government bodies, and public places for mass testing. Developed in collaboration with ICMR, the kits provide results within 30-60 minutes without requiring elaborate infrastructure.
3. Tuberculosis Testing Kits (TBFYND): Sale of rapid TB detection kits to government health initiatives, private healthcare providers, and remote area screening programs. CDSCO approved kit designed for point-of-care use in hard-to-reach areas.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

Acrannolife Genomics develops and commercializes proprietary molecular diagnostic platforms for the early detection and monitoring of chronic and infectious diseases. Its core offer is the Trunome liquid biopsy platform, a US-patented, made-in-India blood test that non-invasively monitors solid organ transplant health (kidney, liver, heart, lungs, pancreas) via cell-free DNA analysis. The company also manufactures and sells point-of-care infectious disease kits: COVIQWIK (COVID-19, RT-LAMP, 30-60 minute results) developed with ICMR, and TBFYND (tuberculosis, CDSCO-approved LAMP, 98.73% accuracy).

Product overview

Acrannolife Genomics is a precision diagnostics company operating two distinct product lines: (1) Trunome Platform for chronic disease care, including Trunome-Tx for post-transplant organ health monitoring across kidney, liver, heart, lungs, and pancreas; and (2) Infectious Disease solutions including COVIQWIK (Covid-19 RT-LAMP testing kit developed with ICMR) and TBFYND (tuberculosis detection kit). The company utilizes proprietary liquid biopsy technology analyzing cell-free DNA (cfDNA) from blood samples for non-invasive disease detection and monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Trunome: A non-invasive liquid biopsy diagnostic test platform for early detection and monitoring of chronic diseases including post-transplant organ health monitoring for kidney, liver, heart, lungs, and pancreas.
• COVIQWIK
• TBFYND
• Trunome GrafAssure

Products and services

• Trunome Post-Transplant Organ Health Monitoring (Trunome-Tx / Trunome GrafAssure) Non-invasive liquid biopsy diagnostic service (Trunome-Tx) for monitoring solid organ transplant health across kidney, liver, heart, lungs, and pancreas through a simple blood draw, using cell-free DNA (cfDNA) and donor-derived cfDNA (ddcfDNA) analysis to detect early rejection. Validated for liver transplant monitoring at 93.33% sensitivity, 94.44% specificity, and 94.12% accuracy, and protected by the Trunome US patent; offered as Trunome GrafAssure through the Technology Development Board-supported indigenous manufacturing program.
• COVIQWIK COVID-19 Testing Kit RT-LAMP-based COVID-19 testing kit co-developed with ICMR that yields results in 30-60 minutes with 100% sensitivity and 100% specificity. Designed for decentralized mass testing in airports, offices, schools, hospitals, and public places without requiring elaborate laboratory infrastructure or high CAPEX.
• TBFYND Tuberculosis Testing Kit Rapid, point-of-care tuberculosis detection kit built on Loop-mediated Isothermal Amplification (LAMP) technology. CDSCO approved with 98.73% accuracy, 98.73% sensitivity, and 100% specificity; provides results within 60 minutes without requiring high-end equipment, suitable for use in remote and hard-to-reach areas and government TB screening programs.

Quantifiable outcome

• 93.33% Sensitivity, 94.44% Specificity, 87.50% PPV, 97.14% NPV, 94.12% Accuracy for ddcfDNA liver transplant monitoring
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• ICMR (Indian Council of Medical Research)coreStrategic or Co-development PartnerCOVIQWIK COVID-19 testing kit was developed in collaboration with ICMR. The RT-LAMP technology was validated and endorsed by ICMR-National Institute of Virology for rapid diagnosis of SARS-CoV-2.
• NIV (National Institute of Virology)coreStrategic or Co-development PartnerPartnership with NIV Mumbai for development of cost-effective, rapid RT-LAMP COVID test kit. The technology was transferred to Chennai and Delhi-based companies for production.
• Journal of Clinical and Experimental HepatologyminorOthersResearch publication partner for peer-reviewed study on Donor-Derived Cell-Free DNA in Liver Transplant Monitoring. The study was accepted for publication on June 27, 2024.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Hologic: Hologic's Panther and Aptima molecular diagnostics platforms compete with Acrannolife in infectious disease molecular IVD, particularly in hospital and reference-lab settings. Hologic represents the broader molecular IVD incumbent competitive set.
• Cepheid (Danaher): Cepheid's GeneXpert system is the global standard for cartridge-based molecular POCT (including Xpert MTB/RIF for TB) and competes with Acrannolife's LAMP-based TBFYND and RT-LAMP COVIQWIK. As an established incumbent with broad menu and installed base, it represents the dominant incumbent benchmark.
• Abbott Molecular: Abbott's m-PIMA and ID NOW platforms are point-of-care molecular NAAT systems, broadly comparable to Acrannolife's decentralized RT-LAMP/LAMP infectious disease kit strategy. Abbott is a benchmark incumbent for global POC molecular diagnostics.
• Roche Diagnostics: Roche offers broad PCR-based molecular IVD menus (cobas, LightCycler) and is a benchmark incumbent for IVD reagent manufacturing. As Acrannolife scales CDSCO-approved IVD kit production at TANSIDCO, it will increasingly compete with Roche for hospital and government lab contracts in India.

Direct peers

• Molbio Diagnostics: Molbio's Truenat platform is a leading Indian point-of-care molecular NAAT system for infectious diseases including TB, directly comparable to Acrannolife's TBFYND LAMP kit. Both are CDSCO-approved, India-manufactured, decentralized molecular diagnostics targeting TB elimination programs.
• Mylab Discovery Solutions: Mylab is an Indian molecular diagnostics company that developed indigenous RT-PCR and rapid test kits (including COVID-19) and supplies government health programs, making it a direct domestic peer to Acrannolife's COVIQWIK and TBFYND in the Indian IVD manufacturing space.
• Natera: Natera's Prospera donor-derived cell-free DNA test is the closest direct global competitor to Trunome-Tx, offering non-invasive transplant rejection monitoring using cfDNA. Both companies commercialize dd-cfDNA blood tests across multiple solid organs, making Natera the most direct comparable.
• CareDx: CareDx's AlloSure (dd-cfDNA) and AlloMap (gene-expression) products are direct competitors to Acrannolife's Trunome-Tx franchise across kidney, liver, and heart transplant monitoring. Both target the same clinicians and transplant centers with non-invasive rejection diagnostics.
• Guardant Health: Guardant Health is a cfDNA liquid biopsy leader in oncology, applying the same core molecular counting/sequencing architecture that Acrannolife's Trunome platform uses. It is a direct peer on liquid biopsy technology, though Acrannolife is currently focused on transplant and infectious disease rather than oncology.

Regional players

• Thyrocare Technologies: Thyrocare is a leading Indian diagnostic laboratory network providing affordable preventive and specialized testing. While not a direct molecular diagnostics competitor, it represents the Indian regional diagnostic-services landscape that Acrannolife's Trunome-Tx testing service may partner with or compete against for hospital specimen routing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/acrannolife
• Facebookfacebook.com/acrannoLife
• LinkedInlinkedin.com/company/acrannolife-genomics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acrannolife Genomics